Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Blocklisting - Interim Review

23rd May 2017 12:10

SHIRE PLC - Blocklisting - Interim Review

SHIRE PLC - Blocklisting - Interim Review

PR Newswire

London, May 23

BLOCK LISTING SIX MONTHLY RETURN

May 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Name of applicant:Shire plc
Name of scheme:Shire Sharesave Scheme
Period of return:From:November 23, 2016To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:184,611
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):17,079
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:167,532

Name of applicant:Shire plc
Name of scheme:Shire Portfolio Share Plan
Period of return:From:November 23, 2016To:May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:769,615
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):405,083
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:364,532

Name of applicant:Shire plc
Name of scheme:Shire Employee Stock Purchase Plan
Period of return:From:November 23, 2016To:May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:244,057
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):6,359
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:237,698

Name of applicant:Shire plc
Name of scheme:Shire Long Term Incentive Plan 2015
Period of return:From:November 23, 2016To:May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:2,836,412
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):145,740
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:2,690,672

Name of applicant:Shire plc
Name of scheme:Shire Global Employee Stock Purchase Plan
Period of return:From:November 23, 2016To:May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:1,604,243
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):3,400
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:1,600,843

 

Name of applicant:Shire plc
Name of scheme:Baxalta Exchange Awards
Period of return:From:November 23, 2016To:May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:20,488,204
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):2,492,337
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:17,995,867

Name of contact:Sarah Rixon, Company Secretarial Assistant
Telephone number of contact:01256 894000

For further information please contact:

Investor Relations
Ian Karp[email protected]+1 781 482 9018
Robert Coates[email protected]+44 1256 894874
Media
Lisa Adler[email protected]+1-617 588 8607
Debbi Ford[email protected] +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com


Related Shares:

Shire
FTSE 100 Latest
Value8,602.92
Change-2.06